Development of donepezil-induced hypokalemia following treatment of cognitive impairment / 영남의대학술지
Yeungnam University Journal of Medicine
;
: 65-69, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-875569
ABSTRACT
Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
Yeungnam University Journal of Medicine
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS